View:
August 9, 2024
Kristen Fortney, Ph.D.
Chief Executive Officer
BioAge Labs, Inc.
1445A South 50th Street
Richmond, California 94804
Re: BioAge Labs, Inc.
Amendment No. 2 to Draft Registration Statement on Form S-1
Submitted August 5, 2024
CIK No. 0001709941
Dear Kristen Fortney Ph.D.:
We have reviewed your amended draft registration statement and have the
following
comment.
Please respond to this letter by providing the requested information
and either submitting
an amended draft registration statement or publicly filing your registration
statement on EDGAR.
If you do not believe this comment applies to your facts and circumstances or
do not believe an
amendment is appropriate, please tell us why in your response.
After reviewing the information you provide in response to this letter
and your amended
draft registration statement or filed registration statement, we may have
additional
comments. Unless we note otherwise, any references to prior comments are to
comments in our
July 18, 2024 letter.
Amendment No. 2 to Draft Registration Statement on Form S-1
Business
Indication expansion opportunities, page 143
1. We note your response to comment 3 and re-issue in part. Please disclose
who conducted
the third-party cross-over trial, whether it was preclinical or
clinical, and specify the third-
party preclinical literature.
August 9, 2024
Page 2
Please contact Eric Atallah at 202-551-3663 or Vanessa Robertson at
202-551-3649 if
you have questions regarding comments on the financial statements and related
matters. Please
contact Jimmy McNamara at 202-551-7349 or Joshua Gorsky at 202-551-7836 with
any other
questions.
Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Julia Forbess